According to GlobalData’s medical device pipeline database, 350 Cardiac Disease devices are in various stages of development globally. GlobalData’s report Cardiac Disease provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 118 are in active development, while the remaining 233 are in an inactive stage of development. There are 59 products in the early stages of development, and the remaining 59 are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. A cardiac disease test is a blood test that can be used to measure levels of cholesterol, triglycerides, and other substances that can increase the risk of heart disease.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Cardiac Disease pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Cardiac Disease devices. Overall, most of these Cardiac Disease pipeline devices are being developed by private entities.
Key players involved in the active development of Cardiac Disease include BBB Technologies, Upstream Medical Technologies, Roche Diagnostics International, Siemens Healthcare Diagnostics, SomaLogic, Abbott Diagnostics, China Medical Technologies, Cavadis, Beckman Coulter and Ortho Clinical Diagnostics.
For a complete picture of the developmental pipeline for Cardiac Disease devices, buy the report here.